📊 SILO Key Takeaways
Is Silo Pharma, Inc. (SILO) a Good Investment?
Silo Pharma is a pre-revenue stage pharmaceutical company with severe fundamental deterioration: $18K quarterly revenue against $1.6M operating losses, negative gross margins, and $822.6K quarterly cash burn. With $3.9M cash and current burn rate, the company has approximately 19 months of runway before requiring dilutive financing or restructuring.
Silo Pharma, Inc. Key Strengths (SILO)
- Zero debt on balance sheet with positive $5.7M stockholders equity
- Strong current ratio (9.65x) and quick ratio (9.57x) provide near-term liquidity
- Cash position of $3.9M covers operational needs for several quarters
SILO Stock Risks: Silo Pharma, Inc. Investment Risks
- Near-zero revenue ($18K) with no demonstrated commercialization progress in pharma sector
- Negative gross margin (-14.8%) indicates product/service economics are not viable at current scale
- Quarterly cash burn of $822.6K creates unsustainable depletion of cash reserves with limited runway
- Operating losses of $1.6M per quarter against minimal revenue demonstrates no profitability pathway
- No insider trading activity and lack of revenue traction suggest management confidence concerns
- Pharmaceutical development requires multi-year timelines; current burn rate incompatible with industry requirements
Key Metrics to Watch
- Quarterly revenue growth and customer acquisition metrics
- Monthly cash burn rate and revised runway analysis
- Operating expenses and cost structure changes
- Any clinical trial milestones or FDA approval announcements
- Financing activities and dilution from capital raises
Silo Pharma, Inc. (SILO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.65x current ratio provides a solid financial cushion.
SILO Profit Margin, ROE & Profitability Analysis
SILO vs Healthcare Sector: How Silo Pharma, Inc. Compares
How Silo Pharma, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Silo Pharma, Inc. Stock Overvalued? SILO Valuation Analysis 2026
Based on fundamental analysis, Silo Pharma, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Silo Pharma, Inc. Balance Sheet: SILO Debt, Cash & Liquidity
SILO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Silo Pharma, Inc.'s revenue has grown significantly by 78% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.19 indicates the company is currently unprofitable.
SILO Revenue Growth, EPS Growth & YoY Performance
SILO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $18.0K | -$1.0M | $-0.12 |
| Q3 2025 | $18.0K | -$801.7K | $-0.12 |
| Q2 2025 | $18.0K | -$801.7K | $-0.19 |
| Q1 2025 | $18.0K | -$801.7K | $-0.23 |
| Q3 2024 | $18.0K | -$660.2K | $-0.21 |
| Q2 2024 | $18.0K | -$801.7K | $-0.31 |
| Q1 2024 | $18.0K | -$801.7K | $-0.28 |
| Q3 2023 | $18.0K | -$604.1K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Silo Pharma, Inc. Dividends, Buybacks & Capital Allocation
SILO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Silo Pharma, Inc. (CIK: 0001514183)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SILO
What is the AI rating for SILO?
Silo Pharma, Inc. (SILO) has an AI grade of D with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SILO's key strengths?
Claude: Zero debt on balance sheet with positive $5.7M stockholders equity. Strong current ratio (9.65x) and quick ratio (9.57x) provide near-term liquidity.
What are the risks of investing in SILO?
Claude: Near-zero revenue ($18K) with no demonstrated commercialization progress in pharma sector. Negative gross margin (-14.8%) indicates product/service economics are not viable at current scale.
What is SILO's revenue and growth?
Silo Pharma, Inc. reported revenue of $18.0K.
Does SILO pay dividends?
Silo Pharma, Inc. does not currently pay dividends.
Where can I find SILO SEC filings?
Official SEC filings for Silo Pharma, Inc. (CIK: 0001514183) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SILO's EPS?
Silo Pharma, Inc. has a diluted EPS of $-0.12.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SILO's fundamental grade?
Based on our AI fundamental analysis in June 2026, Silo Pharma, Inc. has a D grade with 92% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SILO stock overvalued or undervalued?
Valuation metrics for SILO: ROE of -29.0% (sector avg: 15%), net margin of -9,137.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SILO's AI grade for 2026?
Our dual AI analysis gives Silo Pharma, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SILO's free cash flow?
Silo Pharma, Inc.'s operating cash flow is $-822.6K, with capital expenditures of N/A. FCF margin is -4,563.5%.
How does SILO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -9,137.5% (avg: 12%), ROE -29.0% (avg: 15%), current ratio 9.65 (avg: 2).